Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
9 papers
Recent·Most cited
J. Musa, F. Cidre-Aranaz, M.-M. Aynaud…·T. G. P. Grunewald
This study shows how a dominant oncogene and regulatory germline variants together influence tumor growth, survival, and drug response in Ewing sarcoma.
K. Steinestel, E.-P. Jansen, M. Trautmann…·W. Hartmann
This study shows FAK promotes migration and prevents apoptosis in Ewing sarcoma via Y397 phosphorylation, suggesting FAK inhibitors could target metastasis.
A. Marchetto, S. Ohmura, M. F. Orth…·T. G. P. Grunewald
The paper identifies SOX6 as a therapeutic target in Ewing sarcoma by showing its role in elevating ROS levels, making the disease vulnerable to ROS-inducing drugs.
J. S. Gerke, M. F. Orth, Y. Tolkach…·T. G. P. Grunewald
This study identifies subtype-specific prognostic biomarkers in prostate adenocarcinoma, showing that their prognostic value depends on TMPRSS2-ERG fusion status.
M. Dallmayer, J. Li, S. Ohmura…·T. G. P. Grunewald
This study identifies CALCB as a direct EWSR1-FLI1 target in Ewing sarcoma and shows that targeting the CALCB/RAMP1-axis inhibits tumor growth.
M. F. Orth, J. S. Gerke, T. Knosel…·T. G. P. Grunewald
This study identifies AMPD2 as a prognostic biomarker for undifferentiated pleomorphic sarcoma using transcriptome analysis, immunohistochemistry, and functional assays.
M. C. Baldauf, J. S. Gerke, A. Kirschner…·T. G. Grunewald
The paper introduces RAVEN, a software tool that identifies cancer-specific genes encoding MHC-affine peptides from gene expression data, validated across 50 cancer types.
M. C. Baldauf, M. F. Orth, M. Dallmayer…·T. G. P. Grunewald
This study identifies ATP1A1, BCL11B, and GLG1 as specific immunohistochemical markers for Ewing sarcoma, offering high specificity for diagnosis.